title: Respective roles of the 14 kDa and 85 kDa phospholipase A2 enzymes in human monocyte eicosanoid formation.
abstract: Human monocytes possess both the cytosolic 85 kDa phospholipase (PLA) A2 and a 14 kDa PLA2 and are capable of simultaneously producing prostanoids (PG), leukotrienes (LT) and platelet activating factor (PAF). As the exact roles of the two enzymes in monocyte lipid mediator formation was unclear, both selective PLA2 inhibitors and antisense were used to elucidate their respective roles. Reduction in 85 kDa PLA2 cellular protein levels by initiation site-directed antisense (SK 7111) or exposure to the 85 kDa PLA2 inhibitor, arachidonyl trifluormethyl ketone (AACOCF3), prevented A23187 or zymosan-stimulated monocytes prostanoid formation but not LTC4 or PAF production. This confirmed the important role of the 85 kDa PLA2 in prostanoid formation but indicated a less significant role in LT or PAF biosynthesis. Alternatively, treatment of monocytes with the selective, active-site-directed 14 kDa PLA2 inhibitor, SB 203347, totally inhibited LT and PAF formation, while prostanoid formation was not altered. Addition of 20 uM exogenous arachidonic acid (AA) to monocytes exposed to SB 203347 did not alter A23187-induced LTC4 generation, indicating that SB 203347 had no effect on downstream AA metabolizing enzymes in this setting. Taken together, these results provide evidence that the 14 kDa PLA2 provides substrate for monocyte LT and PAF formation, while the 85 kDa PLA2 plays a more significant role in the formation of PG.
authors.affiliation: Department of Immunopharmacology, SmithKline Beecham Pharmaceuticals, King of Prussia, PA 19406, USA. Lisa_A_Marshall@SBPHRD.com
authors.forename: L A
authors.initials: LA
authors.lastname: Marshall
authors.forename: B
authors.initials: B
authors.lastname: Bolognese
authors.forename: A
authors.initials: A
authors.lastname: Roshak
mesh_terms: D016718:Arachidonic Acid / Q000096:biosynthesis; D001095:Arachidonic Acids / Q000494:pharmacology; D015777:Eicosanoids / Q000096:biosynthesis*; D004791:Enzyme Inhibitors / Q000494:pharmacology; D006801:Humans; D066298:In Vitro Techniques; D007527:Isoenzymes / Q000037:antagonists & inhibitors / Q000737:chemistry / Q000378:metabolism*; D015289:Leukotrienes / Q000096:biosynthesis; D008954:Models, Biological; D008970:Molecular Weight; D009000:Monocytes / Q000187:drug effects / Q000378:metabolism*; D016376:Oligonucleotides, Antisense / Q000494:pharmacology; D010741:Phospholipases A / Q000037:antagonists & inhibitors / Q000737:chemistry / Q000378:metabolism*; D054467:Phospholipases A2; D010972:Platelet Activating Factor / Q000096:biosynthesis; D011453:Prostaglandins / Q000096:biosynthesis; D013449:Sulfonamides / Q000494:pharmacology
chemical_list: D001095:Arachidonic Acids; D015777:Eicosanoids; D004791:Enzyme Inhibitors; D007527:Isoenzymes; D015289:Leukotrienes; D016376:Oligonucleotides, Antisense; D010972:Platelet Activating Factor; D011453:Prostaglandins; C095801:SB 203347; D013449:Sulfonamides; C081565:arachidonyltrifluoromethane; D016718:Arachidonic Acid; D010741:Phospholipases A; D054467:Phospholipases A2